Correlation Between Replimune and Alnylam Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Replimune and Alnylam Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Replimune and Alnylam Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Replimune Group and Alnylam Pharmaceuticals, you can compare the effects of market volatilities on Replimune and Alnylam Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Replimune with a short position of Alnylam Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Replimune and Alnylam Pharmaceuticals.

Diversification Opportunities for Replimune and Alnylam Pharmaceuticals

0.28

Correlation Coefficient

Replimune  Alnylam Pharmaceuticals

Modest diversification

The 3 months correlation between Replimune and Alnylam is 0.28. Overlapping area represents the amount of risk that can be diversified away by holding Replimune Group and Alnylam Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Alnylam Pharmaceuticals and Replimune is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Replimune Group are associated (or correlated) with Alnylam Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Alnylam Pharmaceuticals has no effect on the direction of Replimune i.e., Replimune and Alnylam Pharmaceuticals go up and down completely randomly.

Pair Corralation between Replimune and Alnylam Pharmaceuticals

Given the investment horizon of 90 days Replimune Group is expected to under-perform the Alnylam Pharmaceuticals. In addition to that, Replimune is 1.31 times more volatile than Alnylam Pharmaceuticals. It trades about -0.05 of its total potential returns per unit of risk. Alnylam Pharmaceuticals is currently generating about 0.08 per unit of volatility. If you would invest  23,601  in Alnylam Pharmaceuticals on December 30, 2024 and sell it today you would earn a total of  3,245  from holding Alnylam Pharmaceuticals or generate 13.75% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Replimune Group  vs.  Alnylam Pharmaceuticals

Replimune Group

Risk-Adjusted Performance

Very Weak

Over the last 90 days Replimune Group has generated negative risk-adjusted returns adding no value to investors with long positions. Despite conflicting performance in the last few months, the Stock's basic indicators remain quite persistent which may send shares a bit higher in April 2025. The latest mess may also be a sign of long-standing up-swing for the company institutional investors.

Alnylam Pharmaceuticals

Risk-Adjusted Performance

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Alnylam Pharmaceuticals are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Alnylam Pharmaceuticals showed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Replimune and Alnylam Pharmaceuticals

The main advantage of trading using opposite Replimune and Alnylam Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Replimune position performs unexpectedly, Alnylam Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alnylam Pharmaceuticals will offset losses from the drop in Alnylam Pharmaceuticals' long position.

The idea behind Replimune Group and Alnylam Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.